Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma

Huang, Qiang; Ji, Mengyou; Li, Feiran; Li, Yufeng; Zhou, Xuehua; Hsueh, Chi‐Yao; Zhou, Liang

doi:10.1016/j.mcp.2023.101895

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, VEGF-C has been measured successfully via ELISA assay in plasma in other studies. In one study of laryngeal squamous cell carcinoma patients, low plasma VEGF-C was shown to correlate with longer overall survival compared to high plasma VEGF-C. 21 Another study showed VEGF-C measured in plasma of breast cancer patients to be higher compared to controls and benign breast tumor patients. 22 Additionally, a previous study in PCa and mast cells, all of which might be more active in remission.…”

Section: Discussionmentioning

confidence: 99%

Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity

Mullen,

Das,

Ziamiavaghi

et al. 2023

The Prostate

View full text Add to dashboard Cite

BackgroundNeuropilin 2 (NRP2) expression in tissue is an independent prognostic factor for aggressive prostate cancer. Since the NRP2 pathway activation is thought to occur in part through secondary resistance, quantification of NRP2 in initial tissue biopsy specimens collected at diagnosis may have limited utility in identifying patients at highest risk for morbidity and mortality. Given that metastatic tissue is only occasionally obtained for analysis, there is a need for development of a plasma biomarker indicative of NRP2 pathway activation to potentially inform prostate cancer prognosis. Therefore, we investigated if plasma levels of NRP2 or vascular endothelial growth factor C (VEGF‐C), a known soluble ligand of NRP2, are prognostic for prostate cancer. We hypothesized that plasma NRP2 and VEGF‐C would be associated with more advanced disease or relapsed disease.MethodsNRP2 and VEGF‐C levels were quantified by enzyme‐linked immunoassay in plasma samples obtained from 145 prostate cancer patients in an opportunistic biobank. These patients were either (1) newly diagnosed (N = 28), (2) in remission (N = 56), or (3) relapsed disease (N = 61). Plasma samples from 15 adult males without known malignancy served as a comparator cohort. Statistical analysis was performed to investigate the association of plasma NRP2/VEGF‐C with patient outcomes, adjusting for age, race, prostate‐specific antigen (PSA), Gleason score, and tumor stage at diagnosis.ResultsNeither NRP2 nor VEGF‐C levels were significantly different in cancer patients compared to noncancer controls. We observed no clear association between plasma NRP2 and disease severity. Increased plasma VEGF‐C was significantly associated with disease remission and correlated with Stage I/II and intermediate‐risk Gleason score. Neither NRP2 nor VEGF‐C correlated with PSA level.ConclusionsAlthough tissue NRP2 expression correlates with severe disease, this was not observed for plasma NRP2. Plasma NRP2 levels did not correlate with disease severity or relapse. VEGF‐C was highest in patients in remission and with less severe disease. Future investigation is needed to identify noninvasive methods to assess tumor NRP2 status.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity

Mullen,

Das,

Ziamiavaghi

et al. 2023

The Prostate

View full text Add to dashboard Cite

show abstract

“… 75 Huang et al further demonstrated that VEGF-C is a noninvasive diagnostic biomarker of laryngeal squamous cell carcinoma (LSCC). 76 …”

Section: Role Of Inflammation-related Pathways In the Progression Of ...mentioning

confidence: 99%

The Role of Inflammation-Associated Factors in Head and Neck Squamous Cell Carcinoma

Li,

Zeng,

Liu

et al. 2023

JIR

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC), which originates in the head or neck tissues, is characterized by high rates of recurrence and metastasis. Inflammation is important in HNSCC prognosis. Inflammatory cells and their secreted factors contribute to the various stages of HNSCC development through multiple mechanisms. In this review, the mechanisms through which inflammatory factors, signaling pathways, and cells contribute to the initiation and progression of HNSCC have been discussed in detail. Furthermore, the diagnostic and therapeutic potential of targeting inflammation in HNSCC has been discussed to gain new insights into improving patient prognosis.

show abstract

“…The development of tumours is a complex process in which angiogenesis plays a crucial role, enabling tumours to grow and metastasize through the formation of new blood vessels. As the tumour progresses, tumour cells are subjected to various forms of stress, including hypoxia, which can lead to their death through necrosis or apoptosis, consequently releasing DNA into the extracellular environment, known as circulating cell-free DNA (cfDNA) [ 28 , 29 , 30 , 31 , 32 ]. In breast cancer, it has also been shown that an increase in circulating tumour DNA (ctDNA) (the fraction of cfDNA that originates from tumour cells) can be a good indicator and may be used to monitor disease progression and response to treatment in patients with advanced breast cancer [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

A Preliminary Evaluation of Advanced Oxidation Protein Products (AOPPs) as a Potential Approach to Evaluating Prognosis in Early-Stage Breast Cancer Patients and Its Implication in Tumour Angiogenesis: A 7-Year Single-Centre Study

Napiórkowska-Mastalerz,

Wybranowski,

Bosek

et al. 2024

Cancers

View full text Add to dashboard Cite

Breast cancer (BrC) is a highly prevalent tumour among women. The high incidence and mortality rate of BrC prompts researchers to search for new markers that will provide information on the possible impact of the therapy on the risk of cancer-related events. This study aimed to investigate whether the level of advanced oxidation protein products (AOPPs) may have a potential impact on disease-free (DFS) and overall survival (OS) in BrC patients with early-stage cancer. Additionally, we tried to assess the relationship between AOPPs and angiogenic parameters. In this study, the pre- and post-treatment AOPP levels were examined in the serum of 70 newly diagnosed BrC women. The receiver operating characteristic curve identified pre- and post-treatment AOPPs to be above 9.37 μM and 10.39 μM, respectively, as the best cut-off values to predict the risk of cancer relapse. Additionally, Kaplan–Meier survival analysis indicated that pre- and post-treatment AOPPs above 9.37 μM and 10.39 μM were associated with significantly poorer OS. The uni- and multivariate Cox regression analysis highlighted that lower levels of pre- and post-treatment AOPPs were associated with a longer duration without relapse or cancer-related death. A positive correlation between concentrations of pre-treatment AOPPs and vascular endothelial growth factor A, and negative correlations with levels of soluble forms of vascular endothelial growth factor receptor type 1 and 2, were found. In conclusion, AOPPs appear to have an important role in predicting cancer-related events and may potentially serve as a simple prognostic marker in clinical practice.

show abstract

Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma

Cited by 4 publications

References 39 publications

Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity

Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity

The Role of Inflammation-Associated Factors in Head and Neck Squamous Cell Carcinoma

A Preliminary Evaluation of Advanced Oxidation Protein Products (AOPPs) as a Potential Approach to Evaluating Prognosis in Early-Stage Breast Cancer Patients and Its Implication in Tumour Angiogenesis: A 7-Year Single-Centre Study

Contact Info

Product

Resources

About